Eric Lefkofsky (CEO of Tempus and co-founder of Groupon):
“Treating a cancer patient without the benefit of modern software is the same as driving at night without headlights. If you don’t introduce some amount of data, you will end up going down the wrong path.”

AI and machine learning have received a lot of attention over the last year, poised to become a big game changer in many industries, including the healthcare sector. The industry is responding with a rise in potential applications with companies developing new approaches and innovative tools. The pharma sector is engaging AI to provide analytical solutions to accelerate drug development, while the tech industry is entering the healthcare market to build winning solutions, and the clinical sector is advancing AI for diagnostic decision making and treatment evaluation.

At the Precision Medicine World Conference PMWC 2018 Silicon Valley, Eric Lefkofsky (CEO of Tempus) was interviewed by Atul Butte (Director, Institute for Computational Health Sciences, UCSF). Eric shared his views on the biggest challenges in cancer treatment and how to best address them by finding value in the data. Find the full interview on the PMWC blog.

Eric: “We view this data challenge as a problem that can be solved. Meaning, we can put rich data into the hands of oncologists, pathologists, radiologists, surgeons, and researchers and we believe if you do that, you end up saving most probably 100,000 of the 600,000 patients a year from dying.”

The benefits of a data-driven healthcare are manifold and undeniable. Yet, for AI and machine learning to create the value needed, significant hurdles must be overcome. To arm the physician and researcher with the data they need, and to ensure patients will contribute to public data initiatives, orthogonal data sets (both clinical and molecular data) must be combined, proper bioinformatics and analytics tools must be in place, clinical data must be extracted from sometimes arcane medical record systems, and the data must be structured, cleansed, and understood. Clearly, a lot of work still needs to be done, but as Vinod Khosla commented at PMWC 2018 Silicon Valley:

“AI will do more for medicine in the next 20 years than all the biological sciences combined. AI is something that human beings can’t comprehend as it is exceeding the human capability, and as such it is challenging to fully understand the potential and how it will impact our lives, or healthcare in particular.”

PMWC 2018 Michigan, June 6-7, is a great opportunity for everybody in the field to learn, contribute, and help build a foothold for AI to become the reality in healthcare. We have invited (and continue to invite) a number of leading scientists and critical thought leaders who will review and cover relevant subjects in AI and deep/machine learning for two dedicated AI and machine learning sessions.

Here is the list of thought leaders that are among our confirmed presenters:

Eric Topol
The Scripps Research Institute (TSRI)

Francis Collins
National Institutes of Health (NIH)

Eric Lefkofsky
Tempus

Nancy Cox
Vanderbilt University

Jenna Wiens
University of Michigan

George Sledge
Stanford University

Susan A. Murphy
Harvard University

Julie Iskow
Medidata

In addition, we’ll have presentations from the following organizations:

  • Ayasdi
  • Athelas
  • Children’s Mercy
  • Ciitizen
  • CosmosID
  • Data4Cure
  • Fred Hutchinson
  • Genomenon
  • Guardant Health
  • Harvard
  • IBM
  • Immusoft
  • iNDX Technology
  • Karius
  • LOOL Health
  • Medical College of Wisconsin
  • Medidata
  • Mendel.ai
  • Natera
  • NorthShore University Health System
  • One Medical
  • Providence
  • Scripps Research Institute
  • Stanford
  • Strata Oncology
  • Tempus
  • Theravance
  • University of Michigan
  • UCSF
  • Vanderbilt University
  • ViewCure
  • Vertex
  • Wayne State University
Looking forward to seeing many of you at the upcoming PMWC 2018 Michigan conference scheduled for June 6-7 in Ann Arbor, MI.

In addition, we’ll have presentations from the following organizations:

  • Ayasdi
  • Athelas
  • Children’s Mercy
  • Ciitizen
  • CosmosID
  • Data4Cure
  • Fred Hutchinson
  • Genomenon
  • Guardant Health
  • Harvard
  • IBM
  • Immusoft
  • iNDX Technology
  • Karius
  • LOOL Health
  • Medical College of Wisconsin
  • Medidata
  • Mendel.ai
  • Natera
  • NorthShore University Health System
  • One Medical
  • Providence
  • Scripps Research Institute
  • Stanford
  • Strata Oncology
  • Tempus
  • Theravance
  • University of Michigan
  • UCSF
  • Vanderbilt University
  • ViewCure
  • Vertex
  • Wayne State University

Looking forward to seeing many of you at the upcoming PMWC 2018 Michigan conference scheduled for June 6-7 in Ann Arbor, MI.

Interview with Daniella Beller, Manager, Maccabi Research Institute Biobank

Q: What makes the Maccabi Research Institute biobank unique?

A: To explain the uniqueness of the Maccabi Biobank (named “Tipa” in Hebrew which means “drop” or “just a little”), first you must know a little about Maccabi.

Read More

Why We Need Public-Private Partnerships (PPP) To Foster Drug Discovery

Investments in pharma R&D has substantially increased over the last decades. Yet there appears to be no clear correlation to the number of newly approved drugs. This fact is accompanied by ever-increasing healthcare costs, fueled by an aging population and the parallel rise in the chronic disease burden.

Read More

Precision Medicine: A Decade of Improving the Standard of Care

In January, PMWC will host its 2019 Silicon Valley event, the largest Precision Medicine conference in the world with over 2,500 attendees gathering at the Santa Clara Convention Center. We are humbled and honored to have reached this stage of growth and are looking forward to continuing our work with key stakeholders and decision makers across the industry to ever strengthen this forum for exchange of critical and timely topics, to move the field of precision medicine forward and to improve the Standard of Care.

Read More

Interview with David Hong from Karius

Q: What need is Karius addressing?

A: Physicians often have difficulty pinpointing the exact pathogen that is causing disease. Conventional diagnostics like blood cultures or PCR can have poor sensitivity due to pretreatment with antibiotics, the breadth of potential pathogens present, and the requirement for invasive procedures to access deep-seated infections.

Read More

Interview with Charles Jaffe, MD, PhD from HL7

Q: What need is HL7 addressing?

A: For more than three decades, HL7 has provided the platform to enable global health data interoperability. This is more important than ever, as the cost of healthcare has increased exponentially, and the complexity of clinical evidence has grown to an almost unmanageable state.

Read More

Interview with Eden Haverfield from Invitae

Q: What need is Invitae addressing?

A: Our mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Invitae is uniquely positioned to answer some of life’s most serious and complex questions with the highest quality genetics and at an affordable price.

Read More

Call by Ralph Snyderman (Duke U.) for Big Changes to Get to the Next Level of Precision Medicine

Beyond next-generation gene sequencing and developing diagnostic tools and targeted therapies, theoverall approach to clinical care has to be re-envisioned to fulfill the promise of precision medicine. Care must move from sporadic treatment of episodic disease (a reactive mode) to predicting disease and then acting to prevent and mitigate it (a proactive mode).

Read More

Interview with William Hearl From Immunomic Therapeutics, Inc.

Q: What need is Immunomic Therapeutics, Inc. addressing?

A: Immunomic Therapeutics’ nucleic acid vaccines have the potential to utilize the body’s natural biochemistry to develop a broad immune response, including antibody production, cytokine release and critical immunological memory.

Read More

Interview with Ralph Snyderman from Duke University

Q: What are some of the critical contributions that academic institutions and medical centers are making to implement and accelerate precision medicine?

A: Over the past decade, the field of precision medicine has created technologies enabling far more personalized and effective health care delivery. Many of the most dramatic advances have come in the field of oncology but targeting care to the needs of the individual is rapidly achieving broader applications.

Read More

Interview with Catherine Reinis Lucey from UCSF

Q: What research are you or your lab focusing on and why, and what problem(s) are you trying to solve?

A: My work involves designing, implementing and studying innovations in medical education that allow our medical schools to fulfill our social contract to improve the health of our communities and reduce the suffering of our patients.

Read More

Interview with Gunnar Carlsson from Ayasdi

Q: What need is Ayasdi addressing?

A: Ayasdi is pioneering the application of artificial intelligence to value-based care by targeting two of the most complex problems in healthcare: population risk stratification and clinical variation management.

Read More

Interview with Nikole Kimes from Siolta Therapeutics

Q: What need is Siolta Therapeutics addressing?

A: Chronic diseases, including inflammatory diseases such as asthma, now represent the leading cause of mortality and morbidity worldwide.

Read More

Note from Dr. Patrick Conway, President & CEO, Blue Cross and Blue Shield NC to PMWC

VC activity is booming in healthcare, with second quarter drawing in $5.1 billion in capital. That is 22% of the total $23 billion raised by all VC-based companies in the U.S., according to latest Pricewaterhouse Coopers quarterly report.

Read More

Interview with Atul Sharan, Co-founder and CEO, CellMax Life

Q: CellMax has developed non-invasive blood tests based on Circulating tumor cells CTC. How do you see these tests being adopted clinically?

A: Survival rates are greater than 90% for cancers that are detected at an early stage.

Read More

Interview with Wendell Jones from Q² Solutions | EA Genomics

Q: What need is Q² Solutions | EA Genomics addressing?

A: As a leading provider of genomic services in clinical trials and discovery, Q² Solutions | EA Genomics advances science by harnessing technological expertise to drive understanding of the human genome and disease biology to detect the effects of therapies.

Read More
University of Michigan

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

  • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
    • Digital Phenotyping
    • Precision Public Health
    • Pharmacogenomics
    • The Microbiome
    • Rare Disease Diagnosis
    • Digital Health/Health and Wellness
    • Early Days of Life Sequencing
    • Diversity in Precision Medicine
    • Resilience
    • AI and Machine Learning
    • Gene Editing
    • Large Scale Bio-data Resources to Support Drug Development (PPPs)
    • Point-of Care Dx Platform
    • FDA Efforts to Accelerate PM
    • Implementation into Health Care Delivery
    • Next Gen. Workforce of PM
    • Immunotherapy
    • Robust Clinical Decision Support Tools
    • Creating Clinical Value with Liquid Biopsy ctDNA, etc.
    • Neoantigens
    • Emerging Technologies In PM

The Precision Medicine World Conference (PMWC), held annually in Silicon Valley, is coming back to North Carolina for its 2nd Conference back at Duke University on September 24-25, 2018.

PMWC 2018 Duke, the 15th installment of the conference, will spotlight the explosion of biomedical technologies, driving initiatives that enable the translation of precision medicine into direct improvements in health care.

 

    • Track 1 will showcase sessions on the latest advancements in precision medicine which include, but are not limited to:
      • Digital Phenotyping
      • Precision Public Health
      • Pharmacogenomics
      • The Microbiome
      • Rare Disease Diagnosis
      • Digital Health/Health and Wellness
      • Early Days of Life Sequencing
      • Diversity in Precision Medicine
      • Resilience
      • AI and Machine Learning
      • Gene Editing
      • Large Scale Bio-data Resources
        to Support Drug Development (PPPs)
      • Point-of Care Dx Platform
      • FDA Efforts to Accelerate PM
      • Implementation into Health Care Delivery
      • Next Gen. Workforce of PM
      • Immunotherapy
      • Robust Clinical Decision Support Tools
      • Creating Clinical Value with Liquid Biopsy
        ctDNA, etc.
      • Neoantigens
      • Emerging Technologies In PM
  • Track 2- PMWC 2018 Duke Showcase, will enable 15-minute company presentations on latest novel technologies. Apply to present here.
big data diagnostics session

Clinical Dx Showcase

crispr showcase

Emerging Therapeutics Showcase

NGS Showcase

Genomic Profiling Showcase

AI Showcase Session Image

AI and Data Sciences Showcase

  • Luminary and Pioneer Awards, honoring individuals who contributed, and continue to contribute, to the field of Precision Medicine
  • 500+ multidisciplinary attendees, from across the entire spectrum of healthcare, representing different types of companies, technologies, and medical centers with leadership roles in precision medicine

[chimpy_lite_form]

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!